Dan A. Dixon

High Impact

Professor

UAMS

Also affiliated: Northwestern University (1991–1993); Grand Rapids Community College (2013); University of Geneva (2020); Novartis (Switzerland) (2011); MACOM (United States) (2005); The University of Texas MD Anderson Cancer Center (2020); Johns Hopkins University (1999); University of Kansas (2018–2024); University of South Carolina (2005–2023); Pfizer (United States) (2023); Vanderbilt University (2003); University of Utah (1998–2003); Huntsman Cancer Institute (1998–2003); The Ohio State University Wexner Medical Center (2020); University Medical Center (2017); In-Q-Tel (2012); The University of Kansas Cancer Center (2012–2025); Office of the Chief Scientist (2020); South Carolina Cancer Alliance (2007–2010); University Hospital and Clinics (2017); Institute of Human Genetics (2000); Cancer Research Center (2009–2012); University of Kansas Medical Center (2012–2023); Winthrop Rockefeller Foundation (2025–2026); Jackson and Tull (United States) (2020); Novartis Institutes for BioMedical Research (2011); Texas Southern University (2001); University of California, Davis (1993–1995); Michigan State University (2013); Vanderbilt University Medical Center (2003–2004); The University of Texas Health Science Center at Houston (1993)

Faculty Researcher

COM | Biochemistry & Molecular Biology

46 h-index 203 pubs 8,587 cited

Research Areas

Biomedical Subjects

Links

ORCID Google Scholar Lab Website Research Group UAMS TRI Profile

OverviewAI-generated summary

Dan A. Dixon's research focuses on understanding the molecular mechanisms that drive cancer development and progression, with a particular emphasis on the role of RNA-binding proteins and extracellular vesicles. His work investigates how these components influence gene expression and cellular behavior in various cancer types, including colorectal and pancreatic cancer.

Dixon has published research on the tumor-initiating stem cell's ability to shape its microenvironment into an immunosuppressive and pro-tumorigenic niche. He also studies the targeting of the RNA-binding protein HuR in cancer, exploring how HuR posttranscriptionally regulates key pro-tumorigenic factors like YAP1 in pancreatic cancer. Furthermore, his group investigates the involvement of IMP1/IGF2BP1 in colorectal cancer extracellular vesicles and how exosomes containing HuR can promote lung cell proliferation by stabilizing c-Myc mRNA. His work also includes examining the effects of compounds like pyrvinium pamoate on pancreatic cancer cells under nutrient-depleted conditions by targeting mitochondria, and the pro-tumorigenic activities promoted by extracellular vesicles from APCMin/+ mice via the NF-κB signaling pathway.

With a career marked by extensive publication and high citation counts (h-index: 46, total citations: 8,542), Dixon leads an active research group at the University of Arkansas for Medical Sciences, where he holds the position of Professor in the Department of Biochemistry & Molecular Biology.

Metrics

h-index: 46
Publications: 203
Citations: 8,587

Selected Publications

Mapping risk: Spatial analysis of 2,4-D herbicide emissions and colorectal cancer (2025)

Environmental Challenges DOI OpenAlex
Post-transcriptional regulation by HuR in colorectal cancer: impacts on tumor progression and therapeutic strategies (2025)

Frontiers in Immunology 1 citation DOI OpenAlex
Abstract 2358: XPO1 inhibition serves as an effective chemoprevention strategy in colorectal cancer mouse models (2025)

Cancer Research DOI OpenAlex
Suppression of stress granule formation is a vulnerability imposed by mutant p53 (2025)

Nature Communications 5 citations DOI OpenAlex

View all publications on OpenAlex →

Grants & Funding

As listed on this researcher's institutional profile.

Nano-Engineered Lab-on-a-Chip for Assessing HuR-Regulated Exosomes for Cancer Monitoring and Targeted Therapy NIH/Nat. Cancer Institute via University of Kansas Principal Investigator